Craft

Inotiv

Stock Price

$1.8

2024-10-29

Market Capitalization

$47.3 M

2024-10-29

Revenue

$513 M

FY, 2025

Inotiv Summary

Company Summary

Overview
Inotiv (formerly known as BioAnalytical Systems) is a company that provides research services to pharmaceutical and biotechnology companies. It operates in two business segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment supports the discovery and nonclinical and clinical development needs of researchers and clinicians for primarily small-molecule drug candidates, as well as biotherapeutics and biomedical devices. The RMS segment offers access to a range of small and large purpose-bred animal research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas, in addition to diet and bedding.
Type
Public
Status
Active
Founded
1974
HQ
West Lafayette, IN, US | view all locations
Website
https://www.inotiv.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • John Sagartz

    John Sagartz, Chief Strategy Officer and Director

  • Greg Beattie

    Greg Beattie, Chief Operating Officer, DSA

  • Michael A. Baim

    Michael A. Baim, Senior Vice President of Analytical Operations, BASi

  • Jeff Krupp

    Jeff Krupp, Chief Human Resources Officer

LocationsView all

1 location detected

  • West Lafayette, IN HQ

    United States

    2701 Kent Ave

Inotiv Financials

Summary Financials

Revenue (Q2, 2026)
$117.7M
Net income (Q2, 2026)
($32.5M)
Cash (Q2, 2026)
$15.2M
EBIT (Q2, 2026)
($19.3M)
Enterprise value
$926.1M

Footer menu